Article Versions Notes

Turkes F, Bryant A, Begum R, Davidson M, Kalaitzaki E, Aresu M, Lazaro-Alcausi R, Bryant J, Rana I, Chua S, et al. Ibrutinib in c-MYC and HER2 Amplified Oesophagogastric Carcinoma: Results of the Proof-of-Concept iMYC Study. Current Oncology. 2022; 29(4):2174-2184. https://doi.org/10.3390/curroncol29040176

Turkes, Fiona, Annette Bryant, Ruwaida Begum, Michael Davidson, Eleftheria Kalaitzaki, Maria Aresu, Retchel Lazaro-Alcausi, Jane Bryant, Isma Rana, Sue Chua, and et al. 2022. "Ibrutinib in c-MYC and HER2 Amplified Oesophagogastric Carcinoma: Results of the Proof-of-Concept iMYC Study" Current Oncology 29, no. 4: 2174-2184. https://doi.org/10.3390/curroncol29040176

Turkes, F., Bryant, A., Begum, R., Davidson, M., Kalaitzaki, E., Aresu, M., Lazaro-Alcausi, R., Bryant, J., Rana, I., Chua, S., Aronson, L., Hulkki-Wilson, S., Fribbens, C., Watkins, D., Rao, S., Starling, N., Cunningham, D., Chong, I. Y., & Chau, I. (2022). Ibrutinib in c-MYC and HER2 Amplified Oesophagogastric Carcinoma: Results of the Proof-of-Concept iMYC Study. Current Oncology, 29(4), 2174-2184. https://doi.org/10.3390/curroncol29040176